AbbVie Data Demonstrate Efficacy and Cost-Effectiveness of T...
Phase 3 CALM study shows that closely monitoring disease activity using the tight control approach with adalimumab led to improved endoscopic and clinical outcomes in patients with moderate to severe ...
